Nano Holdings, Inc. (4571)

Market cap
¥10.6B
P/E ratio
-10.2x
NANO MRNA develops RNA-based drug candidates including mRNA and siRNA therapies, then licenses them to pharmaceutical companies for late-stage development and commercialization.
Period EndTotal non-current assets (Million JPY)YoY (%)
Mar 31, 2025375-38.41%
Mar 31, 2024609-45.39%
Mar 31, 20231,116+34.06%
Mar 31, 2022832-9.43%
Mar 31, 2021919-10.33%
Mar 31, 20201,025-35.24%
Mar 31, 20191,582+101.37%
Mar 31, 2018786+58.08%
Mar 31, 2017497-53.54%
Mar 31, 20161,070+116.22%
Mar 31, 2015495
AI Chat